- BNF:
- Immune system & malignant disease
- Status:
- Red
- Decision Date:
- March 2018
Comments
RED:
- NICE TA870 - Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (Decision date - March 2023)
NHS England drug. Available through CDF
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again